Foundations - Gene-ius Prescribing
- Pharmacogenomics (PGx): The science studying how genetic variations influence an individual's response to medications. It bridges pharmacology and genomics.
- Core Goals:
- Enhance drug efficacy (↑).
- Reduce adverse drug reactions (ADRs ↓).
- Significance: Crucial for personalized medicine, guiding drug choice and dosing based on unique genetic profiles for safer, more effective treatments.
⭐ Pharmacogenomics aims to tailor drug therapy at the individual level based on genetic makeup.
Star Players - Medication Matchmakers
| Gene | Drug(s) | Key Impact (Polymorphism) | Clinical Action (NEET PG Focus) | Notes (📌 Mnemonic / ⭐ Fact / 🇮🇳 India) |
|---|---|---|---|---|
| CYP2C19 | Clopidogrel | Poor Metabolizers (PM): ↓ active drug, ↑ MACE risk | Consider alternative (prasugrel, ticagrelor). | 📌 Clopidogrel Cries Poorly. 🇮🇳 High LoF allele prevalence in Indians. |
| CYP2D6 | Codeine, Tramadol | PM: ↓ analgesia; Ultra-Rapid Metabolizers (UM): ↑ toxicity | Codeine: Avoid in PM/UM. Tramadol: Adjust/avoid. | |
| TPMT, NUDT15 | Thiopurines (Azathioprine, 6-MP) | ↓ enzyme activity: ↑ myelosuppression risk | Dose reduction or alternative. NUDT15 variants common in Asians. | |
| HLA-B*5701 | Abacavir | Positive: ↑ severe hypersensitivity reaction (HSR) risk | Mandatory screening. Contraindicated if positive. | ⭐ > HLA-B*5701 screening mandatory before abacavir for HSR prevention. |
| VKORC1, CYP2C9 | Warfarin | Variants alter sensitivity & metabolism | Genotype-guided dosing (consider for initiation). | |
| SLCO1B1 | Statins (Simvastatin) | c.521T>C: ↓ uptake, ↑ myopathy risk with simvastatin >20mg | ↓ simvastatin dose / alternative statin. |
Clinical Integration - Lab to Bedside
Integrating pharmacogenomics (PGx) from lab to clinic personalizes medicine via a structured process.
- PGx Testing Process:
- Pre-test counseling (benefits, limitations).
- Sample collection (blood/saliva).
- Genotyping/Sequencing identifies variants.
- Interpretation: Relates genotype to phenotype, guiding drug choice/dose.
- CPIC Guidelines: Essential for translating genetic data into actionable, evidence-based clinical recommendations for gene-drug pairs.
- Clinical Decision Support Systems (CDSS):
- Integrate PGx data into EHR workflow, alerting prescribers.
- Reactive testing: Drug-specific, ordered when needed.
- Preemptive testing: Panel-based, results available for future decisions.
⭐ CPIC guidelines provide peer-reviewed, evidence-based, and actionable recommendations for gene-drug pairs.
Hurdles & Horizons - Gene Challenges, Future Wins
- Key Barriers:
- Cost of PGx testing.
- Limited clinician education & awareness.
- EMR integration challenges.
- Ethical, Legal, Social Implications (ELSI) like data privacy.
- Slow turnaround time for results.
- Indian Context Challenges:
- Significant genetic diversity.
- Infrastructural & affordability constraints.
- Dearth of India-specific guidelines & population data.
⭐ Lack of clinician education and standardized guidelines are major barriers to widespread PGx implementation.
- Future Horizons:
- Artificial Intelligence (AI) in PGx.
- Polygenic risk scores for complex traits.
- Broader preemptive genetic testing.
High‑Yield Points - ⚡ Biggest Takeaways
- CPIC guidelines provide actionable recommendations for gene-drug interactions.
- CYP2D6 variants impact metabolism of codeine, tamoxifen, and many antidepressants.
- CYP2C19 loss-of-function alleles reduce clopidogrel efficacy; consider alternatives.
- Mandatory HLA-B*5701 testing before abacavir prevents life-threatening hypersensitivity.
- HLA-B*1502 screening (especially in Asian populations) is crucial before carbamazepine to avoid SJS/TEN.
- TPMT and NUDT15 genotyping is essential for thiopurine (azathioprine, 6-MP) dosing to prevent severe myelosuppression.
- Warfarin dosing is significantly influenced by CYP2C9 and VKORC1 polymorphisms.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app
